Wedge Capital Management L L P NC Purchases 2,756 Shares of Luminex Co. (LMNX)

Wedge Capital Management L L P NC boosted its position in Luminex Co. (NASDAQ:LMNX) by 18.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 17,827 shares of the medical instruments supplier’s stock after acquiring an additional 2,756 shares during the period. Wedge Capital Management L L P NC’s holdings in Luminex were worth $540,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Aperio Group LLC boosted its holdings in Luminex by 4.8% in the second quarter. Aperio Group LLC now owns 35,095 shares of the medical instruments supplier’s stock worth $1,036,000 after acquiring an additional 1,611 shares in the last quarter. Martingale Asset Management L P lifted its holdings in shares of Luminex by 1.5% in the second quarter. Martingale Asset Management L P now owns 138,915 shares of the medical instruments supplier’s stock valued at $4,103,000 after purchasing an additional 2,000 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Luminex by 3.4% in the second quarter. Rhumbline Advisers now owns 106,965 shares of the medical instruments supplier’s stock valued at $3,159,000 after purchasing an additional 3,514 shares in the last quarter. California Public Employees Retirement System lifted its holdings in shares of Luminex by 4.0% in the second quarter. California Public Employees Retirement System now owns 93,724 shares of the medical instruments supplier’s stock valued at $2,768,000 after purchasing an additional 3,632 shares in the last quarter. Finally, Legal & General Group Plc lifted its holdings in shares of Luminex by 6.1% in the second quarter. Legal & General Group Plc now owns 91,449 shares of the medical instruments supplier’s stock valued at $2,681,000 after purchasing an additional 5,234 shares in the last quarter. Institutional investors and hedge funds own 82.36% of the company’s stock.

Shares of LMNX opened at $26.61 on Friday. The company has a market cap of $1.24 billion, a P/E ratio of 44.83, a price-to-earnings-growth ratio of 3.26 and a beta of 0.34. Luminex Co. has a 12 month low of $18.62 and a 12 month high of $35.37.

Luminex (NASDAQ:LMNX) last issued its quarterly earnings results on Monday, November 5th. The medical instruments supplier reported $0.05 EPS for the quarter, missing the Zacks’ consensus estimate of $0.08 by ($0.03). The business had revenue of $72.40 million for the quarter, compared to analysts’ expectations of $74.05 million. Luminex had a net margin of 5.65% and a return on equity of 5.99%. The business’s revenue was down 2.3% compared to the same quarter last year. During the same period in the previous year, the business posted $0.13 earnings per share. As a group, research analysts anticipate that Luminex Co. will post 0.57 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Friday, October 12th. Investors of record on Friday, September 21st were given a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.90%. The ex-dividend date of this dividend was Thursday, September 20th. Luminex’s payout ratio is 26.37%.

A number of research analysts have recently weighed in on LMNX shares. BidaskClub lowered Luminex from a “buy” rating to a “hold” rating in a report on Thursday, October 4th. ValuEngine lowered Luminex from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 8th. Zacks Investment Research upgraded Luminex from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Citigroup dropped their target price on Luminex from $34.00 to $33.00 and set a “neutral” rating on the stock in a report on Tuesday. Five analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. Luminex currently has an average rating of “Buy” and a consensus target price of $28.40.

WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another site, it was illegally stolen and reposted in violation of international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/11/10/wedge-capital-management-l-l-p-nc-purchases-2756-shares-of-luminex-co-lmnx.html.

About Luminex

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system.

Featured Article: Technical Analysis of Stocks and What It Means

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply